Product
nivolumab-daratumumab
1 clinical trial
1 indication
Indication
Multiple MyelomaClinical trial
A Phase 2 Study of Nivolumab Combined With Daratumumab With or Without Low-dose Cyclophosphamide in Relapsed/Refractory Multiple MyelomaStatus: Completed, Estimated PCD: 2023-01-25